Yu-Yao Li,Jing Fang,Gui-Zhen Ao
Yu-Yao Li
Cathepsins play an important role in protein degradation and processing. Aberrant cathepsin B or L is closely associated with many serious diseases such as cancer, osteoporosis and autoimmune disorders. Therefore, development of potent and ...
Rodolfo do Couto Maia
Rodolfo do Couto Maia
Neuropathic pain (NP) is one of the most important health problems faced nowadays. NP is a chronic disease that cannot be treated like other pain conditions because it is developed from a nerve injury that evolves into a permanent dysfuncti...
Baoxin Zhang,Junmin Zhang,Shoujiao Peng et al.
Baoxin Zhang et al.
Mammalian thioredoxin reductases (TrxRs) are selenocysteine-containing homodimeric flavin enzymes that catalyze the NADPH-dependent reduction of oxidized thioredoxins. Increasing evidence indicates that TrxRs are potential targets for antic...
Juan Sun,Peng-Cheng Lv,Hai-Liang Zhu
Juan Sun
Bacterial infection has been a consistent and relentless threat to human health because of emerging resistance to existing antibiotics. Therefore, much of the research has been focused on the design of new potent antibacterial agents. Tyros...
Kamal M Dawood,Thoraya A Farghaly
Kamal M Dawood
Four isomeric structures of thiadiazole motifs have outstanding pharmacological inhibitory applications are reported in this review. Thiadiazole nucleus is present in several biologically active natural products and commercial drugs. Most o...
Tao Yu,Yanyan Yang,Yan Liu et al.
Tao Yu et al.
FGFR1 is a well known molecular target for anticancer therapy. Many studies have proved that the regulation of FGFR1 activity is a promising therapeutic approach to treat a series of cancers. Therefore, the development of potent inhibitors ...
Small-molecule inhibitors of hepatitis C virus (HCV) non-structural protein 5A (NS5A): a patent review (2010-2015) [0.03%]
丙型肝炎病毒非结构蛋白5A的小分子抑制剂专利综述(2010-2015)
Yan A Ivanenkov,Vladimir A Aladinskiy,Nikolay A Bushkov et al.
Yan A Ivanenkov et al.
Non-structural 5A (NS5A) protein has achieved a considerable attention as an attractive target for the treatment of hepatitis C (HCV). A number of novel NS5A inhibitors have been reported to date. Several drugs having favorable ADME propert...
Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015) [0.03%]
乙酰胆碱酯酶抑制剂和复能剂的最新研究进展（2012-2015）——专利文献更新
Stanton F McHardy,Hua-Yu Leo Wang,Shelby V McCowen et al.
Stanton F McHardy et al.
Acetylcholinesterase (AChE) is the major enzyme that hydrolyzes acetylcholine, a key neurotransmitter for synaptic transmission, into acetic acid and choline. Mild inhibition of AChE has been shown to have therapeutic relevance in Alzheimer...
Julius Pollinger,Daniel Merk
Julius Pollinger
WY14643 - also known as pirinixic acid - is a versatile fatty acid mimetic that was originally developed as lipid lowering agent without knowledge of its molecular target. Various later studies discovered somewhat promiscuous activity of th...
Bitopic muscarinic agonists and antagonists and uses thereof: a patent evaluation of US20160136145A1 [0.03%]
双位点胆碱激动剂和拮抗剂及其应用：对US20160136145A1专利申请的评估分析
Ulrike Holzgrabe,Michael Decker
Ulrike Holzgrabe
Bitopic M ligands, that is, ligands that interact both with the ortho- and allosteric binding sites of the M receptor subtypes, hold great potential as novel selective for muscarinic acetylcholine (M) ligands for several therapeutic applica...